Torrent Pharmaceuticals has successfully raised ₹12,500 crore through a mix of commercial paper and multiple‑tenure non‑convertible debentures (NCDs) to finance its planned acquisition of a controlling stake in JB Chemicals & Pharmaceuticals.
The fundraising move, completed in January 2026, forms part of the company’s broader strategy to accelerate growth and strengthen its position in the domestic pharmaceutical market.
The funds were raised across a structured debt programme: ₹1,500 crore via one‑year commercial paper, ₹2,000 crore through two‑year NCDs at a 7.45% yield, ₹2,500 crore via three‑year NCDs at 7.60%, ₹3,000 crore through four‑year NCDs at 7.70%, and ₹3,500 crore via five‑year NCDs at 7.80%. Institutional investors including mutual funds, insurance companies, and pension funds participated in the debt subscription.
The capital raise will support Torrent Pharma’s acquisition of JB Chemicals — a deal originally announced in mid‑2025 — and is expected to significantly enhance Torrent’s market footprint. The transaction is projected to reposition Torrent from the seventh to the fifth largest player in the Indian pharmaceutical sector by domestic market share once the deal is completed.
This funding initiative follows regulatory and committee approvals for debt issuance and reflects strong investor confidence in Torrent’s financial strategy and growth prospects amid consolidation trends in the Indian pharma industry.
